6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of April 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Completion of Placement |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: April 7, 2025
2
Exhibit 99.1
Alterity Therapeutics Announces Completion ofPlacement
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA– 7 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced completion of the second tranche of the two-tranche placement initiated earlier this year. Overall A$38.79M of funds were received with participation from Alterity’s CEO and CFO and the majority of the Board of Directors.
David Stamler, M.D., Chief Executive Officer of Alterity, commented, “We are grateful for the strong shareholder support at our Extraordinary General Meeting last week to complete our Placement, giving us the runway to continue to advance our pipeline focused on neurodegenerative diseases. We expect to use the funds from this capital raise to accelerate the regulatory and development activities for ATH434 and to continue research and discovery of novel compounds for major indications such as Parkinson’s disease.”
About ATH434
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 recently announced positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA. A second Phase 2 open-label 2 Biomarker trial in patients with advanced MSA is ongoing. ATH434 has been granted Orphan Drug Designation for the treatment of MSA by the U.S. FDA and the European Commission.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity recently reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains “forward-lookingstatements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,”“anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” andother similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual resultsto differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors”in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,but not limited to the following: statements relating to the Company’s drug development program, including, but not limited to the initiation,progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, ATH434, and any otherstatements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risksand uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketingof the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional futuresources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, butnot limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company’sintellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertaintyof the Company freedom to operate.
Any forward-looking statement made by us inthis press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertakeno obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether asa result of new information, future developments or otherwise.